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Abstract
Background: Several g-secretase inhibitors (GSI) are in clinical trials for the treatment of Alzheimer’s disease (AD).
This enzyme mediates the proteolytic cleavage of amyloid precursor protein (APP) to generate amyloid b protein,
Ab, the pathogenic protein in AD. The g-secretase also cleaves Notch to generate Notch Intracellular domain
(NICD), the signaling molecule that is implicated in tumorigenesis.
Results: We have developed a method to examine live zebrafish that were each treated with g-secretase inhibitors
(GSI), DAPT {N- [N-(3,5-Difluorophenacetyl-L-alanyl)]-S-phenylglycine t-Butyl Ester}, Gleevec, or fragments of Gleevec.
These compounds were first tested in a cell-based assay and the effective concentrations of these compounds that
blocked Ab generation were quantitated. The mortality of zebrafish, as a result of exposure to different doses of
compound, was assessed, and any apoptotic processes were examined by TUNEL staining. We then used
conventional and automatic microscopes to acquire images of zebrafish and applied algorithms to automate
image composition and processing. Zebrafish were treated in 96- or 384-well plates, and the phenotypes were
analyzed at 2, 3 and 5 days post fertilization (dpf). We identified that AD95, a fragment of Gleevec, effectively
blocks Ab production and causes specific phenotypes that were different from those treated with DAPT. Finally, we
validated the specificity of two Notch phenotypes (pigmentation and the curvature of tail/trunk) induced by DAPT
in a dose-dependent manner. These phenotypes were examined in embryos treated with GSIs or AD95 at
increasing concentrations. The expression levels of Notch target gene her6 were also measured by in situ
hybridization and the co-relationship between the levels of Notch inhibition by DAPT and AD95 and the severity of
phenotypes were determined.
Conclusion: The results reported here of the effects on zebrafish suggest that this newly developed method may
be used to screen novel GSIs and other leads for a variety of therapeutic indications.
Background
High throughput screening in invertebrate animals has
emerged as a powerful tool for drug discovery, but
whole vertebrate animal-based high throughput screen-
ing has yet to be developed and refined. The zebrafish is
one of the most cost-effective vertebrates that can be
used for high throughput and high content screens. Phe-
notype-based small molecule screening in zebrafish has
been described in a number of studies [1]. One success-
ful screen used a previously characterized mutant zebra-
fish, Gridlock, that is defective in aortic blood flow
reminiscent of aortic coarctation in humans [2]. A
library of 5,000 small molecules was applied to Gridlock
embryos, followed by manual examination using fluores-
cence microangiography. Two small molecules were
identified to suppress the Gridlock phenotype in a dose-
dependent manner [3]. For non-fluorescent zebrafish,
we have developed algorithms to analyze certain mor-
phological changes in the development of zebrafish
somites [4]. These changes in morphology were linked
to the lack of a component of the g-secretase [5], the
key protease involved in the pathogenesis of Alzheimer’s
disease (AD) [6].
AD is a progressive neurodegenerative disorder that is
pathologically characterized by the presence of extracel-
lular and intracellular lesions known as amyloid plaques
(extracellular) and neurofibrillary tangles (intracellular)
[6]. Amyloid plaques are formed by the accumulation of
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sequential cleavage of amyloid precursor protein (APP)
by b-secretase and g-secretase [6,7]. g-Secretase is an
aspartyl protease that mediates the final cleavage to gen-
erate Ab at residue 40 (Ab40) or 42 (Ab42). It is com-
posed of presenilins (PS1 or PS2), presenilin enhancer
(Pen-2), nicastrin, and Aph-1 [8-10]. PS carry the active
site of the g-secretase [11], and missense mutations in
PS genes account for majority of early onset familial AD
cases. g-Secretase has also been identified as the key
protease involved in the pathogenesis of certain types of
cancers, such as leukemia [12].
Inhibiting the production of Ab by targeting g-secre-
tase constituents is an attractive approach for developing
new treatments of AD, but has potential toxic side
effects. Finding inhibitors of g-secretase complex to sim-
ply block Ab production is no longer a challenge, and a
number of potent g-secretase inhibitors (GSIs) have
been published [13]. However, inhibiting g-secretase not
only prevents APP cleavage and Ab production, but also
blocks the cleavage of other important proteins. g-Secre-
tase cleaves dozens of other type I transmembrane pro-
teins that are critically involved in many metabolic
pathways, including Notch [14]. When both PS1 and its
homolog PS2 are knocked out, the resulting phenotype
is indistinguishable from the Notch knockout, and no
Ab is produced [15]. In mice, Notch deficiency produces
embryonic-lethal phenotypes, demonstrating the essen-
tial nature of Notch signaling in embryonic
development.
Notch signaling plays an important role in health and
disease states during embryonic development through-
out adulthoods. g-Secretase cleaves Notch encoded
transmembrane receptor and activates signal transduc-
tion by releasing the Notch intracellular domain (NICD)
[16]. NICD controls transcription of hairy and enhancer
of split genes, such as hes1 in mammals [17] and her6 in
zebrafish [18,19]. Hes genes are essential effectors of
Notch signaling that regulate the maintenance of undif-
ferentiated cells [20]. In rats lacking Hes1, Hes3,o r
Hes5, all neural stem cells prematurely differentiate into
neurons without generating glial cells. This causes a
wide range of brain defects in size, shape and cell orga-
nization [21]. In zebrafish, Notch is extremely important
in embryonic development and is one of the driving
forces behind neural crest cell differentiation. Inhibition
of Notch signaling leads to extensive defects in organs
derived from neural crest cells. The two most prominent
phenotypes in zebrafish are somitogenesis and pigmen-
tation. These phenotypes are illustrated in many zebra-
fish Notch pathway mutants, such as bea, des, aei,a n d
wit [22,23]. Treating zebrafish with a potent g-secretase
i n h i b i t o r( G S I ) ,D A P T ,a tt h el a t eb l a s t u l as t a g ec a u s e s
defects in somitogenesis and neurogenesis [24].
Similarities have been observed between DAPT-treated
embryos and Notch pathway mutants, and certain phe-
notypes in DAPT treated embryos can be partially res-
cued by microinjection of NICD mRNA [24].
The implication of Notch signaling in cancers arose
from the observation that more than 50% of human T-
cell acute lymphocytic leukemia (T-ALL) has activating
mutations in Notch1 gene. This results in constitutively
active Notch signaling [25]. Perturbed Notch signaling
has been associated with different types of tumor cell
lines. It has been found that g-secretase inhibitors sup-
press these tumorigenesis pathways by reducing Notch
signaling [26-28]. Interestingly, a recent study found
that a combination of enhanced Notch signaling and
Abelson leukemia (Abl) tyrosine kinase activity pro-
motes acute lymphocytic leukemia [29]. Gleevec has
been approved for the treatment of chronic myeloid leu-
kemia and gastrointestinal stromal tumors, and mechan-
istically, Gleevec binds to Abl tyrosine kinase and locks
t h ek i n a s ei na ni n a c t i v ec o n f o r m a t i o nb yi n t e r a c t i n g
with aspartate and phenylalanine [30-32]. In addition,
Gleevec was shown to selectively inhibit APP cleavage
and Ab production at high concentrations [33], in con-
trast to DAPT that blocks both APP and Notch clea-
vages. Therefore, the Gleevec molecule seems to contain
functionalities that cause inhibition of Abl tyrosine
kinase and g-secretase independently. The co-crystal
structure of the Abl tyrosine kinase domain and Gleevec
shows that the pyrimidine and pyridine rings of the
Gleevec overlap with the ATP-binding site via Thr315
[30-32]. The goal of this study is to dissect the structure
of Gleevec and examine the effects of each fragment
both in vitro and in vivo on g-secretase cleavage of APP
and Notch in cultured cell- and whole animal-based
assays. To facilitate data collection, we developed a
semi-automated method for embryo imaging and phe-
notype recording. This approach can be used for future
development of high throughput screening of novel
GSIs and other therapeutic leads for the treatment of
AD, leukemia, and other diseases.
Methods
A. Embryo Treatment
Embryos were placed in a 24-well plate (5-6 embryos/
well). Compounds were dissolved in 1 mL of egg water
(final concentration at 50 μM for DAPT {N- [N-(3,5-
Difluorophenacetyl-L-alanyl)]-S-phenylglycine t-Butyl
Ester}, Gleevec, AD28, AD94, AD95, and 10 μMf o r
AD115; 0.1% DMSO was used as a negative control).
Embryo medium was replaced with the compound con-
taining egg water, and the embryos were incubated at
28°C overnight before survival rate was recorded
and photographic images were taken. Compounds
were applied at two time points, 6 hours and 24 hours
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embryos were de-chorionated in pronase [34]. Embryos
treated at 6 hpf were de-chorionated the following day
after the compound treatment.
B. Blocking Ab production by g-secretase inhibitors
Compounds were dissolved in the DMEM growth media
and applied to ~90% confluent APP-expressing CHO
cells in 96-well plates. After incubation for 4-5 hours at
37°C, cells were centrifuged for 5 minutes at 6000 g,
and supernatant media were collected for Ab measure-
ment by ELISA. Sandwich ELISAs for monomeric Ab
were performed as described [35,36]. The capture anti-
bodies 2G3 (to Ab residues 33-40) and 21F12 (to Ab
residues 33-42) were used for Ab40 and Ab42 species.
The detecting antibody was biotinylated 266 (to Ab resi-
dues 13-28). These antibodies were kindly provided by
Dr. P. Seubert and Dr. D. Schenk (Elan, plc).
C. TUNEL Staining
To examine the apoptotic effect of the compounds on
embryos, TUNEL staining was performed (In Situ Cell
Death Detection Kit, TMR red, Roche). Embryos fixed
in 4% paraformaldehyde overnight at 4°C, de-chorio-
nated, and treated with 1% Triton-X100 in PBS. The
reaction was carried out at 37°C for 1 hour, and all
staining procedures were performed per the instruction
by the manufacturer [5]. The embryos were mounted in
3% methylcellulose and images were acquired under 51×
magnification.
D. In situ Hybridization
In situ hybridization was carried out according to stan-
dard protocols [37] using the her6 probe. Single-
stranded RNA probes against her6 were synthesized
from a cDNA clone (kindly provided by Dr. P Raymond,
University of Michigan, Ann Arbor, MI) using T7 RNA
polymerase after linearization by restriction digest, then
labeled with digoxigenin-UTP (Roche, Basel, Switzer-
land). At least 10 to 20 embryos were examined in each
experiment.
To quantify the expression levels of Notch down-
stream gene her6, we used manual approach to segment
the her6-positive brain regions from the dorsal view
images. The region of interest was manually segmented,
and the intensity of each ROI was quantified. The levels
of her6 expression in DMSO treated embryos were nor-
malized to 1, and relative levels of other embryos were
calculated.
E. Conventional Microscope Imaging
Compound-treated embryos were observed under an
OLYMPUS SZX12 microscope. For examination,
embryos were removed from the compound-containing
medium and placed in 0.4% tricane (3-amino benzoic
acid ethyl ester, Sigma, St. Louis, MO) solution. Upon
anesthetizing, embryos were placed in 3% methylcellu-
lose for positioning and images were recorded with an
OLYMPUS Q-COLOR3 camera. Images were taken at
51× magnification for embryos at 2 dpf, and 40× magni-
fication for embryos at 4 and 6 dpf.
F. Automatic Imaging by In Cell Analyzer 1000
Embryos were treated with compounds at two time
points (6 hpf and 24 hpf) in the 96- or 384-well plates
(1 embryo/well) with compound-containing media (final
concentration at 50 μM for all compounds except for 10
μM of AD115). For image acquisition, tricane was added
to the final concentration of 0.4% in the same plate, and
the plate was loaded into In Cell Analyzer 1000 (Gen-
eral Electric Co., Fairfield, CT). Images of individual
wells were automatically acquired by In Cell Analyzer
1000. From each well of the plate, 4 z-series were
scanned from top to bottom, and 4-6 fields of each well
were taken. Complete coverage of individual wells of the
microtiter plate usually resulted in poor resolution and
prevented further image processing. On average, ~10
minutes were needed for the acquisition of images from
a 384-well plate, and there was no effect on the develop-
ment of zebrafish during this process. Images acquired
by In Cell Analyzer 1000 were processed using
MATLAB (Mathworks, Natick, MA), and fields from
each well were automatically merged using “Merge”
function from Adobe Photoshop Elements (Adobe Sys-
t e m sI n c . ,S a nJ o s e ,C A ) .U s i n gt h e s ea p p r o a c h e s ,t h e
average time used for automatic image acquisition and
processing was significantly reduced compared to con-
ventional microscope-based image acquisition, which
would require approximately 10-20 fold more time to
analyze the same number of animals. Pigmentation was
quantified in a semi-automatic approach. First, manual
drawing of region of interest (ROI) on an image was
carried out, followed by calculation of the optimum
threshold separating the ROI into two classes, pigmenta-
tion and background [38]. The advantage of this method
is that it minimizes the combined intra-class variances
with a moderate computational complexity. However,
the method may generate false-positive and false-nega-
tive due to uneven illumination and noise in the mea-
surement. To circumvent this problem, a size-filter was
used to discard small segmented areas when the areas
are less than a small positive threshold a based on the
prior knowledge that true pigmentation is usually larger
than a pixels. In this work we set a to 10. After seg-
menting the pigmentation, the total area and average
pixel values of pigmentation were computed. The values
of the normal control group were used as the bench-
mark for comparison. If the average pixel density of an
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‘lighter’.
G. In Vitro g-Secretase Cleavage of Notch Substrate
The E. coli generated Notch-based, 100-residue g-secre-
tase substrates N100-Flag were purified as previously
described [39]. N100-Flag substrate contains an initiat-
ing methionine, 99 amino acids that start at the TACE
cleavage site, and a Flag tag. Compounds were mixed
with solubilized g-secretase complex and the in vitro g-
secretase cleavage of Notch substrate was carried out as
previously described [40].
Results
A. Reduction of Ab generation by fragments of Gleevec
Three types of compounds were used to treat zebrafish
embryos: DAPT (a well-established, potent GSI), Glee-
vec (a reported APP-selective GSI), and the fragments of
Gleevec. Four individual Gleevec fragments were
synthesized and designated as AD28, AD94, AD95, and
AD115 (Fig. 1A). An APP overexpressing CHO cell line
7W was treated with individual compounds and the
levels of secreted Ab in the media were measured by
ELISA. Levels of Ab in the media of 7W cells that were
treated with DMSO were normalized to 1, and relative
levels of Ab40 (Fig. 1B) and Ab42 (Fig. 1C) were calcu-
lated. As expected, cells treated with the potent GSI,
DAPT, showed a strong inhibition of the generation of
Ab, even at the concentration of 0.5 μM. At high con-
centration of 50 μM, both Gleevec and AD95 showed
inhibition of Ab production, while AD28 and AD94
showed less inhibition. AD115 failed to inhibit Ab pro-
duction even at 100 μM (Fig. 1B, C).
B. Toxicity of GSI in zebrafish embryos
We routinely generated large clusters of zebrafish
embryos and treated several dozen embryos with each
compound. To assess the effects of these compounds on
Figure 1 Inhibition of Ab production in cultured cells by fragments of Gleevec. A. Structures of Gleevec and its fragments used for the
treatment of cultured cells and zebrafish embryos. Four fragments of Gleevec are named as AD28, AD94, AD95 and AD115. B and C. Inhibition
of g-secretase cleavage of APP was determined by measuring the levels of Ab40 (B) and Ab42 (C) in the conditioned-media by ELISA. Levels of
Ab from cells treated with 0.1% of DMSO were normalized to 1 and used to calculate the relative levels of Ab from cells treated with DAPT,
Gleevec, and its fragments. Standard errors of means are illustrated by bars.
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microscope and quantified embryo survival rate at 1 and
2 dpf (Table 1). When the concentrations of these com-
pounds were at 50 μM, the survival rate of embryos
treated with each of the compounds was close to 100%
except for AD115. None of the embryos treated with 50
μM AD115 survived. When the concentration of AD115
was reduced to 10 μM, all embryos survived at 1 dpf,
and about 90% survived at 2 dpf.
To determine whether these compounds induced
regional apoptosis in zebrafish embryos, apoptotic cell
death was assessed via TUNEL staining (Fig. 2).
Embryos were treated with 50 μM of compounds
( e x c e p tA D 1 1 5w a sa t1 0μM), and TUNEL staining of
these embryos were compared to that of 0.1% DMSO-
treated embryos. While DMSO treated embryos showed
a few apoptotic cells throughout their bodies (Fig. 2A),
compound-treated embryos showed some apoptotic
cells mostly in the tail region. AD28 (Fig. 2D), AD95
(Fig. 2F), and AD115 (Fig. 2G) showed a comparable
number of apoptotic cells to Gleevec-treated embryos
(Fig. 2C). AD94 showed a slightly higher number of
apoptotic cells in the tail compared to the other
embryos (Fig. 2E), and DAPT did not induce extensive
apoptosis in embryos compared to DMSO-treated
embryos (Fig. 2B).
C. Compound Induced Phenotypes in Zebrafish Embryos
The zebrafish embryos treated with different compounds
were examined every 1-2 days up to 6 dpf. Images were
acquired by two methods using conventional microscope
and microscopic instrument In Cell Analyzer. Morpho-
logical phenotypes of zebrafish embryos treated with
DAPT, Gleevec or fragments of Gleevec by conventional
microscope were compared first to document these phe-
notypes (Fig. 3). Images of compound-treated embryos
were acquired at 2 dpf (Fig. 3A), 4 dpf (Fig. 3B) and 6
d p f( F i g .3 C ) .T h eD M S O - t r e a t e de m b r y o ss h o w e da
Table 1 Survival rate of the compound treated embryos.
Cpd Conc. Alive/Total Embryos Alive/Total Embryos
Day 1 Day 2
DMSO 0.10% 35/37 34/35
DAPT 50 μM 32/33 30/32
Gleevec 50 μM 48/50 47/48
AD28 50 μM 28/28 27/28
AD94 50 μM 15/18 15/15
AD95 50 μM 17/18 17/17
AD115 50 μM 0/10 0/0
AD115 10 μ;M 33/34 30/33
Figure 2 Apoptosis in zebrafish embryos treated with compounds. Zebrafish embryos were treated with GSI or fragments of Gleevec at 6
hpf. Embryos were then fixed and subjected to TUNEL staining at 24 hpf. Control embryos were treated with 0.1% DMSO and the remaining
embryos were treated with different GSIs or Gleevec fragments at 50 μM, except for AD115 whose concentration was 10 μM. The majority of
apoptotic cells were observed in the fish tail, but no difference among individual compound-treated embryos was observed. The representative
images from 2 different experiments are presented.
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Page 5 of 16Figure 3 Phenotypes of the embryos treated with GSI, Gleevec, and fragments at 24 hpf. Dorsal view (indicated as “d”, top panel) and
lateral view (indicated as “l”, bottom panel) of embryos are shown. Control embryos treated with 0.1% DMSO show a wild-type phenotype.
Embryos treated with GSI, DAPT, resulted in defects in somitogenesis, eye development, pigmentation, and trunk formation as observed at 2 dpf
(A), 4 dpf (B), and 6 dpf (C). Embryos treated with DAPT, AD94 or AD95 started to show defects at 2 dpf, and phenotypes of remaining embryos
were most obvious at 4 or 6 dpf. The following concentrations were used: 50 μM DAPT, 50 μM Gleevec, 50 μM AD28, 50 μM AD94, 50 μM
AD95, and 10 μM AD115.
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developed normal eyes, straight trunk and tail (Fig. 3A),
V-shaped somites (Fig. 3B and 3C), and normal pigmen-
tation (6 dpf) (Fig. 3C). Embryos treated with DAPT,
the potent GSI known to inhibit both APP and Notch
processing, showed curved tail, a bent trunk (Fig. 3A,
B), smaller eyes, disturbed somites, and a decrease in
pigmentation (Fig. 3C). Almost all Gleevec-treated
embryos developed normally with a phenotype similar
to the wild-type embryos. Only 1 out of 40 Gleevec-
treated fish showed smaller size, and 4 out of 40 showed
a shorter tail. AD28-treated embryos showed normal
pigmentation and V-shaped somites with the pheno-
types similar to wild-type embryos. Less than 20%
(5 out of 28) embryos showed short, slightly curved tails
(Table 2).
Both AD94- and AD95-treated embryos showed defec-
tive phenotypes (Fig 3). While defective phenotypes
were most obvious at the later stages, they were not
lethal, and embryos were alive even at day 7. For AD94,
embryos showed a smaller body size, smaller puffy eyes,
a minor dorsally curved tail, and less pigmentation. For
AD95, all fish displayed a bent trunk (1 embryo had a
severely bent trunk), slightly curved tails, smaller body
size, normal eyes, craniofacial defects, and a lighter pig-
mentation. For AD95-treated embryos, 1 out of 9
assessed zebrafish bodies showed signs of edema. How-
ever, AD95-treated embryos showed normal V-shaped
somites similar to wild-type embryos, which was in con-
trast to DAPT-treated embryos that completely lacked
V-shaped somites (Fig. 3B).
Embryos treated with 10 μM AD115 showed a slightly
abnormal phenotype and variable defects. Overall, 8 out
of 30 fish had edema at 2 dpf, and one embryo dis-
played a bent trunk (data not shown). Among 17
embryos examined at 4 dpf and 6 dpf, 2 embryos had
severe craniofacial abnormalities and did not survive
beyond 6 dpf, 5 embryos showed tumors in the gut
area, and 9 embryos showed craniofacial defects. Normal
V-shaped somites were found among all treated
embryos, and most embryos showed slightly decreased
pigmentation throughout the body and especially around
the swim bladder. The detailed characterization and
comparison of these phenotypes are listed (Table 2) and
used as reference for subsequent analysis of images
automatically acquired by In Cell Analyzer.
D. Automatic image acquisition of compound treated
embryos by In Cell analyzer
In addition to conventional microscope imaging, com-
pound-treated embryos at 6 hpf were imaged by In Cell
Analyzer (Fig. 4). This instrument is commonly used to
perform high-throughput image acquisition of cultured
cells living in 96- or 384-well plates. We adjusted the
instrument for image acquisition of live zebrafish in
microtiter plates. Upon high speed image acquisition by
the instrument, several fields of images from the indivi-
dual wells were automatically merged using “Merge”
command from the Adobe Photoshop Elements. Most
composed images contain the entire zebrafish body, but
some images have truncations due to the nature of
automatic image acquisition (Fig. 4). Because In Cell
Analyzer did not capture the entire population of
embryos in all wells, the number of analyzed zebrafish
images was lower than the number of fish treated with
compounds.
In addition, we de-chorionated embryos at 24 hpf,
transferred them to 96- or 384-well plates and treated
individual embryos with different compounds. Images of
the fish at 2, 3 and 5 dpf were acquired by In Cell Ana-
lyzer and the phenotypes recorded (Fig. 5). No striking
difference in phenotypes between embryos treated at 6
hpf (Fig. 4, Table 3) and 24 hpf (Fig. 5, Table 4) was
observed. Images of DAPT or Gleevec-treated embryos
automatically acquired by In Cell Analyzer at 2 dpf and
3 dpf were similar to those recorded by conventional
microscope. At 5 dpf or 6 dpf, lateral images were diffi-
cult to acquire since most fish maintained a dorsal
orientation due to the development of the swim bladder.
The effects of compounds on pigmentation and
embryo morphology, especially the tail and trunk, were
readily observed. DAPT-treated embryos showed
defects in tail curvature, pigmentation, eyes, and
somite differentiation. Gleevec-treated embryos showed
Table 2 The phenotypes of compound-treated zebrafish imaged by conventional microscope.
Cpd Conc. Size Eye Pigment Tail Trunk
DMSO 0.10% normal normal normal all straight straight
DAPT 50 μM smaller smaller decreased all curved curved
Gleevec 50 μM normal normal normal 4/40 short straight
AD28 50 μM normal normal normal 5/28 slightly curved straight
AD94 50 μM Smaller smaller swollen Decreased all slightly curved curved
AD95 50 μM smaller normal Decreased all slightly curved bent
AD115 10 μM normal normal decreased around swim bladder 11/30 curved straight
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ments, AD28-treated embryos showed no effect at 50
μM. AD94 caused a slight reduction in pigmentation,
and AD115 at 10 μM decreased pigmentation around
the swim bladder and caused curvature in the tails of
several zebrafish. AD95 showed strong inhibition of
Ab production and caused some phenotypes in zebra-
fish. Phenyl thiourea (PTU) is widely used to prevent
pigmentation during embryonic development for
observing transparent zebrafish anatomy. As expected,
all of embryos that were treated with PTU showed
decreased pigmentation (Table 3 and 4).
Zebrafish treated with 50 μM of AD95 did not yield
alteration in pigmentation. However, it caused curvature
of tails with bent trunks. In embryos treated with 50 μM
of AD95 at 24 hpf, a small number of embryos showed
Figure 4 Automatically acquired images of embryos treated with GSI or fragments of Gleevec during early development stage (6 hpf).
Embryos were treated with GSIs or Gleevec fragments at the following concentrations at 6 hpf: 0.1%DMSO, 50 μM for all compounds, except for
10 μM AD115. Images of living zebrafish in microtiter plates were acquired by In Cell Analyzer at 2 dpf (A), 3 dpf (B) and 5 dpf (C), and several
fields of images from the individual wells were automatically merged. Because the instrument acquired several fields that covered a portion of
the microtiter plate well, some images show truncations of the zebrafish.
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μM of DAPT. Apparently, embryos treated with AD95
and DAPT at concentrations that effectively reduced Ab
production (Fig. 1B, C) show quite different phenotypes,
such as the pigmentation (Table 3 and 4) and V-shaped
somites (Table 2), as described earlier.
E. Dose-dependent phenotypic changes in zebrafish
treated with increasing concentration of compounds
To search for a possible dose-dependent effect, a greater
number of embryos were treated with each compound
with two or three different concentrations (Table 5).
Embryos at 24 hpf (Fig. 6) were treated with these com-
pounds and In Cell Analyzer was used to capture
images of embryos at 2 dpf (Fig. 6A), 3 dpf (Fig. 6B)
and 5 dpf (Fig. 6C). DMSO- and untreated-embryos
were used as a control. At 50 μM, DAPT-treated
embryos showed tail curvature and decreased pigmenta-
tion. A minor reduction in pigmentation was also
observed in embryos treated with 5 μMD A P T ,b u tn o
defects in tail curvature or trunk formation were
detected at the lower concentration. The dose-response
Figure 5 Automatically acquired images of embryos treated with GSI or fragments of Gleevec at 24 hpf. Embryos were treated with GSIs
and fragments of Gleevec at 24 hpf, and 50 μM of all compounds, except for 10 μM of AD115, were applied to these embryos. Images of living
zebrafish in microtiter plates were acquired by In Cell Analyzer at 2 dpf (A), 3 dpf (B) and 5 dpf (C), and the same procedures were followed to
automatically merge several fields of images to compose the entire zebrafish.
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those collected by conventional microscope [40]. The
majority of Gleevec-treated embryos showed no defects
in morphology, even at the highest concentration of 100
μM. At this concentration, a decrease of pigmentation
was observed in embryos treated at 24 hpf (Table 5).
AD28 and AD94 did not cause much difference in phe-
notypes when two different concentrations of com-
pounds were used. AD115 was not tested since it was
lethal at doses higher than 10 μM.
While no effect on pigmentation of AD95 at 50 μM
was observed, a minor reduction in pigmentation was
detected when 100 μM of AD95 was used to treat
embryos at 24 hpf (Table 5). The alterations in tails and
trunks were more severe at the high dose of AD95.
Generally, most phenotypes observed in these embryos
were specific and correlated well with the dose of
DAPT, Gleevec and its fragments.
To investigate the mechanistic side effects associated
with GSIs and Gleevec fragments and to explore the
Table 3 Phenotypic description of the embryos treated at 6 hpf followed by automatic image acquisition.
Cpd Embryo Number Conc. Pigment Tail Trunk
DMSO 15 0.1% normal all straight all straight
DAPT 18 50 μM decreased 5/18 curved 10/18 curved
Gleevec 17 50 μM normal all straight 1/17 short
AD28 17 100 μM normal all straight 4/17 short
AD94 12 50 μM decreased all straight all straight
AD95 10 50 μM normal 6/10 curved 6/10 bent
AD115 15 10 μM decreased around swim bladder 2/15 curved all straight
PTU 16 200 μM decreased all straight all straight
Table 4 Phenotypic description of the embryos treated at 24 hpf followed by automatic image acquisition.
Cpd Embryo Number Conc. Pigment Tail Trunk
DMSO 16 0.1% normal all straight all straight
DAPT 14 50 μM decreased 9/14 curved 9/14 curved
Gleevec 17 50 μM normal all straight all straight
AD28 11 100 μM normal 1/11 slightly curved 1/11 short
AD94 6 50 μM 3/6 lighter all straight all straight
AD95 8 50 μM normal 5/8 bent 1/8 edema
AD115 9 10 μM decreased around swim bladder 2/9 curved 5/9 edema
PTU 11 200 μM Decreased all straight all straight
Table 5 Dose-dependent phenotypic alteration in the embryos treated at 24 hpf.
Cpd Embryo Number Conc. Pigment Tail Trunk
DMSO 11 0.1% normal all straight all straight
DAPT 11 50 μM decreased 11/11 curved 11/11 curved
DAPT 9 5 μM decreased slightly all straight 1/9 deformed
DAPT 4 0.5 μM normal all straight all straight
Gleevec 9 100 μM decreased all straight all straight
Gleevec 7 10 μM normal 1/7 curved 1/7 short
Gleevec 7 1 μM normal all straight all straight
AD28 14 100 μM decreased slightly all straight all straight
AD28 4 50 μM normal all straight all straight
AD94 8 100 μM lighter all edema all edema
AD94 4 50 μM lighter all straight all straight
AD95 7 100 μM lighter all curved all bent, 5/7 edema
AD95 4 50 μM normal all bent all bent, 3/4 edema
Untreated 3 normal all straight all straight
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Page 10 of 16Notch signaling that may contribute to these pheno-
types, the expression of the Notch downstream target
gene her6 was examined by in situ hybridization and the
intensity of her6 expression to the effect of inhibitors, i.
e., a loss of her6 staining that corresponds to an inhibi-
tion of g-secretase-mediated Notch signaling, were com-
pared. This approach has been used successfully by us
and others to measure g-secretase cleavage of Notch in
zebrafish [5,41].
In DMSO-treated control embryos, her6 expression
was abundant in the dorsal diencephalon, retinas, ven-
tral midbrain and ventral hindbrain (Fig. 7A). The
expression of her6 was also observed in telencephalon,
olfactory vesicles, branchial arches, ventral hindbrain
Figure 6 Automatically acquired images of embryos treated with increasing concentration of GSI or fragments of Gleevec. Images of
embryos at 2 dpf (A), 3 dpf (B), and 5 dpf (C) were presented. Untreated embryos and 0.1% DMSO-treated embryos displayed similar
phenotypes. Embryos treated with 50 μM DAPT showed a strong phenotype, and much less effect was observed at lower concentrations (5 μM
and 0.5 μM). Gleevec was assessed at 100 μM, 10 μM, 1 μM, and embryos showed no phenotypic alteration. Embryos treated with 100 μMo f
AD95 showed morphologic changes. These changes were not obvious when 50 μM AD95 was used.
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Page 11 of 16and pectoral fins (Fig. 7A). The pattern of her6 staining
is consistent with previous reports [5]. In the presence
of 50 μMD A P T ,t h eher6 expression was lost in most
areas, demonstrating a complete inhibition of g-secretase
activity in the animal (Fig. 7B). The residual g-secretase
activity might remain in olfactory vesicles and telence-
phanlon where weak staining of her6 was detected (Fig.
7B). When embryos were treated with a much lower
concentration of DAPT at 10 μM, weaker staining of
her6 was observed in most areas found in DMSO-trea-
ted embryos, with almost identical staining of her6 in
ventral midbrain (Fig. 7B). Treatment of embryos with
Gleevec (Fig. 7C) and AD28 (Fig. 7D) caused a slight
reduction of her6 staining at 100 μM, and the effect was
much weaker when 50 μM of compounds were used.
The staining of her6 in embryos treated with 50 and
100 μM AD94 (Fig. 7E) was similar to those treated
with Gleevec and AD28. AD115 did not have any effect
on her6 expression and showed identical pattern to con-
trol embryos (Fig. 7G).
AD95 treated embryos showed a regionally specific,
dose-dependent inhibition of her6 expression (Fig. 7F).
At 10 μM, AD95 did not reduce much of her6 staining,
compared to DMSO-treated embryos. When embryos
were treated with 50 μMo r1 0 0μMo fA D 9 5 ,her6
staining was no longer detected in most areas, except
for four regions. No difference in her6 staining in retina
and branchial arches was observed between embryos
treated with 50 μM and 100 μM AD95, but the dorsal
diencephalon and ventral midbrain in embryos treated
with 100 μM had weaker staining than those treated
with 50 μM AD95. The intensity of staining in these
four areas from AD95-treated embryos was reduced
compared to DMSO-treated embryos.
To quantify the intensity of her6 staining, we high-
lighted the regions of interest (Fig 7A’) that corre-
sponded to unique brain structures (Fig. 7A). We
calculated the intensity of all regions of interest and
obtained the average levels of her6 expression in these
embryos (Fig. 8). Overall, there was a reduction of her6
staining in all drug-treated embryos, with DAPT and
AD95 showed most effects. To determine whether there
was direct effect of these compounds on g-secretase
complex, we used in vitro g-secretase activity assay to
examine the Notch cleavage. Using N100 as substrate,
we treated partially solubilized g-secretase with different
Figure 7 Effect of GSI and fragments of Gleevec on Notch target gene her6 expression. Embryos were treated with the compounds at 24
hpf and fixed at 48 hpf in 4% formaldehyde. In situ hybridization was performed to stain her6 staining. In control embryos, her6 expression was
abundant in the dorsal diencephalon, retinas, ventral midbrain and ventral hindbrain, and it was lower in telencephalon, olfactory vesicles,
branchial arches, ventral hindbrain and pectoral fins A, these regions are indicated by arrows; A’, the her6-positive brain regions from the dorsal
view images were manually segmented; A”, the same embryo was illustrated for the comparison of staining intensity. B-G, her6 expression in
embryos treated with different concentrations of DAPT, Gleevec, or fragments of Gleevec.
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Page 12 of 16compounds at 100 μM .W h i l ew ef o u n dm o s tc o m -
pounds did not have any effect on Notch cleavage in
vitro, AD 28. AD115 and DAPT showed inhibition of
Notch cleavage (Table 6).
Discussion
The strength of image acquisition of living zebrafish in
96-and 384-well plates is fast data collection since no
manual intervention was necessary for image recording.
More importantly, the images obtained were a high qual-
ity that is comparable to those images captured by a con-
ventional microscope. Instead of using transgenic
zebrafish that express green fluorescent protein, wild
type zebrafish embryos were routinely treated with
different drugs and bright field images were acquired. For
the first time, images of living zebrafish arrayed in a
microtiter plate were acquired uniformly. The use of
microtiter plate is an industrial standard for in vitro
assays, such as enzymatic assays or cell-based metabolic
assays.
Matlab and Adobe Photoshop Elements software were
used for the composition and processing of automati-
cally acquired images with minimum manual interven-
tion. Due to the size of zebrafish embryos and the
resolution that is required for phenotype analysis, the
difficulties in capturing the entire embryo in 96- or 384-
well plates reflect a primary weakness of this approach.
In this regard, housing zebrafish embryos in 384-well
plates is better because less blank space is left in the
images. Furthermore, compared to images of zebrafish
housed in 96-well plates, a higher number of images
contained a portion of zebrafish embryos living in 384-
well plates, which allows easier image processing by
algorithms. It was noticed that parts of the zebrafish
images were still missing after automatic composition as
shown in several figures. This problem was approached
by using more embryos and extracting essential biologi-
cal information from these images that were composed
and processed by Matlab and Adobe Photoshop Ele-
ments. Further development should be pursued to make
this widely useful for drug screening in zebrafish.
Figure 8 Quantification of Notch target gene her6 expression in embryos treated with GSI or fragments of Gleevec.B a s e do nt h e
segmented region of interest as highlighted in Fig. 7 A’, the intensity of each ROI was quantified. The levels of her6 expression in DMSO treated
embryos were normalized to 1, and relative levels of other embryos were calculated. Different regions of embryos were quantified, and the
average of staining intensity of embryos treated with an individual compound was presented by a horizontal line in red, and the bar represents
the standard error of means.
Table 6 In vitro inhibition of Notch cleavage by AD28
and AD115.
Cpd Conc. In vitro Inhibition of Notch Cleavage
DMSO 0.10% -
DAPT 100 μM+
Gleevec 100 μM-
AD28 100 μM+
AD94 100 μM-
AD95 100 μM-
AD115 100 μM+
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Page 13 of 16Zebrafish is an ideal vertebrate for primary toxicity
studies in whole animals because of their cost-effective-
ness, the ease of drug delivery, and their high sensitivity
to toxins. Among all compounds at the tested concen-
trations, apoptosis was observed within a few cells.
However, the effect was not massive and was compar-
able to the DMSO-treated embryos. In two independent
experiments, AD94 showed a slightly higher apoptotic
phenotype in the tail region than AD95 and DMSO-
treated embryos. However, DAPT- and AD95-treated
embryos showed defects in the tail and trunk develop-
ment, but had fewer apoptotic cells than AD94. The
occurrence of apoptosis in the tail region may not be
the cause for morphological changes in the trunk since
this effect was observed with all compounds tested.
Therefore, perhaps compound-produced defects are
more mechanistic toxicities induced by the blockage of
specific pathways, e.g., an inhibition of Notch signaling
rather apoptosis.
The simplification of high throughput drug screening
in whole animals was illustrated in this test of zebra-
fish that were treated with different concentrations of
various compounds. Although we had only used a few
concentrations in this study, this limitation could be
resolved in the future when more concentrations are
tested for potential lead compounds. The number of
images varied among compounds, depending on fish
survival, positioning, and timing of photo acquisition.
Images taken at earlier stages, such as 2 or 3 dpf, were
usually more informative since embryos were immobile
and both dorsal and lateral views could be obtained.
At the later stages, sometimes only dorsal view can be
imaged, as zebrafish mainly maintain a dorsal position.
Nevertheless, we have successfully obtained high-qual-
ity images of zebrafish growing in 384 well plates, and
the advance we have achieved is not only the quality
of current zebrafish images but also the quantity of
potential images we can acquire in a short period. The
scope of developing a complete set of techniques to
automatically acquire living zebrafish in a 384 well
plates evolves with the advance of optical instruments
and computing power. The current set of techniques
allow a bench scientist to perform drug screening in a
living vertebrate, and further automation could be
developed, e.g., applying robotics for liquid handling.
Exploration of this technique should be pursued to
make it widely useful for drug screening in vertebrate
animals.
In this study, phenotypes of zebrafish treated with
known g-secretase inhibitors, DAPT, Gleevec, and its
fragments were examined. DAPT-treated embryos
showed most defects in tail curvature, pigmentation and
craniofacial structures as previously reported [42]. Over
90% of the Gleevec-treated embryos displayed a wild-
type phenotype, and a few embryos showed a short, but
not curved tail. One of the smaller fragments of Gleevec,
AD28, has the least effect in all of the embryonic studies
p e r f o r m e d .T h i sm a yb ed u et ot h es i m p l i c i t yo fi t s
structure such that AD28 may not have key moieties or
interactions necessary for subsequent findings observed
with Gleevec and AD95.
Fragment AD115 lacked Ab inhibition and caused
mortality of all fish at 50 μM. Lowering the concentra-
tion of AD115 to 10 μMa l s op r o d u c e de m b r y o n i c
defects, such as pigmentation defects around the swim
bladder and defects in craniofacial development. Also,
even at this lower concentration, bumps around the gas-
trointestinal tract were observed. These results suggest
that AD115 has significance differences in its structure
from both Gleevec and AD95 such that treatment of
zebrafish embryos with AD115 yield undesirable effects
versus the overall results observed with both Gleevec
and AD95. These differences in findings indicate that
there are compounds within a chemical series or analogs
thereof that could set the stage for identifying improved
candidate compounds as potential therapeutic agents.
The results indicate that AD95 clearly reduces Ab
production but also affects the morphology of zebrafish
embryos as does AD94 and AD115. If compounds such
as AD95 were to be pursued as potential GSIs as a pos-
sibly therapy for the treatment of AD, Notch processing
w o u l dh a v et ob ee x a m i n e di nm u c hd e t a i l s ,a n dA D 9 5
and analogs need to be further explored for selectively
inhibiting APP processing. Since APP and Notch are
competitively processed by g-secretase [43], it is essential
to selectively inhibit the cleavage of APP substrate and
not Notch. It is interesting that AD95-treated embryos
showed normal V-shaped somites unlike DAPT-treated
embryos. Perhaps DAPT and AD95 block g-secretase
differently and perturb unrelated downstream pathways
which are partly illustrated by somitogenesis, another
interesting facet of this research to further explore.
While Gleevec, AD28 and AD94 showed slight reduc-
tion of her6 staining, their phenotypes were not comple-
tely identical. An animal treated with compounds
usually show many phenotypes, and some of them are
related to Notch signaling. We do not expect that all
phenomenon found in these fish are caused by altered
Notch signaling, as other metabolic pathways might be
changed in the presence of these compounds. Similarly,
several compounds showed different potencies in vitro
and in vivo, strongly suggesting that additional compo-
nents are involved in mediating the effect of GSI and
fragments of Gleevec.
Conclusion
Two methods were used to acquire images of zebrafish
embryos that were treated with DAPT, Gleevec, and
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Page 14 of 16fragments of Gleevec, the conventional microscope ima-
ging and a new semi-automated image acquisition
method. Easy compound delivery and good resolution of
images result in the detailed examination of the effects
of potential drugs on the phenotype of zebrafish. Hence,
this approach provides a platform for a high-throughput
screen of a library of compounds in a whole animal and
establishes the zebrafish as a model vertebrate for
screening therapeutic agents for AD and other diseases.
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